<DOC>
	<DOCNO>NCT01099137</DOCNO>
	<brief_summary>Dual combination therapy metformin sulphonylurea commonly use combination regimen treat patient type 2 diabetes . But , treatment dual combination therapy often unsuccessful achieve glycaemic control patient type 2 diabetes . In set , use insulin often next therapeutic step . Recently , dipeptidyl peptidase ( DPP ) -IV inhibitor increasingly use clinical practice . It well establish DPP-IV inhibitor improve glycemic control patient type 2 diabetes . But , study glucose lower effect DPP-IV inhibitor ( vildagliptin ) Type 2 diabetes patient dual combination therapy sulfonylurea agent metformin.The researcher hypothesize DPP-IV inhibitor add-on therapy combination sulfonylurea agent metformin favorable glucose lower effect type 2 diabetic patient . The researcher plan investigate change HbA1C fast glucose 24 week treatment vildagliptin ( DPP-IV inhibitor ) combination sulfonylurea agent metformin type 2 diabetic patient .</brief_summary>
	<brief_title>Effect Vildagliptin Type 2 Diabetes Treated With Sulphonylurea Metformin</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Vildagliptin</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes HbA1c ≥ 7 % Age ≥ 18 Contraindication Vildagliptin Pregnant breast feeding woman Type 1 diabetes , gestational diabetes , diabetes secondary cause Chronic hepatitis B C ( except healthy carrier HBV ) Liver disease ( AST/ALT &gt; 3fold upper limit normal ) Renal failure ( Cr &gt; 2.0 ) Cancer within 5 year Not appropriate oral antidiabetic agent Medication affect glycemic control Disease affect efficacy safety drug Other clinical trial within 30 day</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>90 Years</maximum_age>
	<verification_date>May 2014</verification_date>
	<keyword>Diabetes</keyword>
	<keyword>Vildagliptin</keyword>
	<keyword>insulin</keyword>
	<keyword>C-peptide</keyword>
</DOC>